← Back to Search

Mucolytic Agent

NAC for COVID-19 (NACinCOVID2 Trial)

Phase 2

Waitlist Available

Research Sponsored by Cambridge Health Alliance

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 weeks starting the day after enrollment

Awards & highlights

NACinCOVID2 Trial Summary

This trial is testing if NAC can help lessen symptoms and the duration of symptoms for people with COVID-19.

Who is the study for?

This trial is for individuals who have tested positive for COVID-19 within the past 7 days. It's not suitable for pregnant women or those already hospitalized due to COVID.Check my eligibility

What is being tested?

The study aims to see if taking N-acetylcysteine (NAC) orally can reduce the severity and length of COVID-19 symptoms compared to a placebo, which has no active ingredients.See study design

What are the potential side effects?

Possible side effects of NAC may include nausea, vomiting, rash, and headache. The placebo is unlikely to cause any direct side effects since it doesn't contain an active drug.

NACinCOVID2 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 weeks starting the day after enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 weeks starting the day after enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks starting the day after enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Symptom duration

Symptom severity

Secondary outcome measures

Need for higher level of care/hospitalization

NACinCOVID2 Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: NACExperimental Treatment1 Intervention

Group receiving intervention/study drug NAC

Group II: PlaceboPlacebo Group1 Intervention

Group receiving placebo

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

N-acetylcysteine

2008

Completed Phase 4

~1290

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

AlturixUNKNOWN

The Thoracic FoundationUNKNOWN

Cambridge Health AllianceLead Sponsor

57 Previous Clinical Trials

20,352 Total Patients Enrolled

2 Trials studying COVID-19

278 Patients Enrolled for COVID-19

Media Library

N-acetylcysteine (Mucolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05074121 — Phase 2

COVID-19 Research Study Groups: Placebo, NAC

COVID-19 Clinical Trial 2023: N-acetylcysteine Highlights & Side Effects. Trial Name: NCT05074121 — Phase 2

N-acetylcysteine (Mucolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05074121 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it feasible for healthcare recipients to join this research endeavor currently?

"This trial is no longer enrolling patients, as the listing was last updated on January 20th 2022. However, 1863 clinical studies are presently recruiting participants with respiratory tract infections and 38 medical trials related to N-acetylcysteine have opened their doors for recruitment."

Answered by AI

In what medical contexts is N-acetylcysteine commonly indicated?

"N-acetylcysteine can be a successful treatment for corneal ulceration, acute rhinitis, and acetaminophen poisoning."

Answered by AI

What possible adverse effects could arise from N-acetylcysteine consumption?

"There is empirical evidence pointing towards the safety of N-acetylcysteine, which resulted in a score of 2. However, since this trial is only at Phase 2 level, there are no data yet to support its efficacy."

Answered by AI

How many participants have registered for this experiment?

"Unfortunately, recruitment for this trial has concluded. It was initially posted on March 31st 2022 and its most recent update occurred January 20th of the same year. If you are searching for other studies, there is currently a plethora of research - 1863 trials concerning respiratory tract infections and 38 involving N-acetylcysteine - actively recruiting participants."

Answered by AI

What other investigative treatments have been assessed utilizing N-acetylcysteine?

"At present, there are 38 different clinical trials being conducted on N-acetylcysteine with 7 in the late stages of testing. Though many of these tests are based out of New york City, 44 distinct sites have been identified for evaluation purposes."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

NAC for Attenuation of COVID-19 Symptomatology

Melisa Lai-Becker 2024. "NAC for Attenuation of COVID-19 Symptomatology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05074121.

All > Coronavirus